Benzinga | Jan 12, 2022 08:05AM EST

SVB Leerink Maintains Outperform on Blueprint Medicines, Lowers Price Target to $120

SVB Leerink analyst Andrew Berens maintains Blueprint Medicines (NASDAQ:BPMC) with a Outperform and lowers the price target from $132 to $120.